BioSpace News Archive

Albany College of Pharmacy and Health Sciences (ACPHS) announces the expansion of its Albany campus through the acquisition of a state-of-the-art medical and life sciences facility located at 150 New Scotland Avenue.

ClexBio, an early-stage biotech company developing next-generation tissue engineered grafts for transplant, is announcing the appointment of two new members to its Board of Directors.

Vast Therapeutics announces promising results with a nitric oxide releasing drug candidate under investigation for infections caused by Mycobacterium abscessus, a multi-drug resistant bacteria for which there are currently no FDA-approved treatments.

Hyloris Pharmaceuticals SA (Euronext Brussels: HYL) a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today provided additional details about the United States (U.S.) Food and Drug Administration (FDA)’s review of the New Drug Application (NDA) for the registration of Maxigesic IV®.

Scholar Rock (NASDAQ: SRRK), today announced an e-poster presentation by Thomas Crawford, M.D., on the design of the company’s ongoing SAPPHIRE Phase 3 clinical trial in spinal muscular atrophy (SMA) at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022) in Brussels, Belgium (July 5 – 9, 2022).

Syros Pharmaceuticals, a leader in the development of medicines that control the expression of genes, announced the grant of restricted stock unit awards for an aggregate of 48,400 shares of Syros common stock to two newly hired employees in connection with their commencement of employment with Syros.

ImmunoGen, Inc. announced that on June 30, 2022, the compensation committee of the Company’s Board of Directors approved grants of non-qualified stock option awards to purchase an aggregate of 1,295,950 shares of its common stock to twenty-seven new employees under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as amended.

Cullinan Oncology, Inc. announced that the compensation committee of the Company’s Board of Directors granted stock option awards to purchase an aggregate of 70,000 shares of its common stock to two employees outside Cullinan Oncology, Inc’s 2021 Stock Option and Incentive Plan.

G1 Therapeutics, Inc., a commercial-stage oncology company, announced the grant of inducement stock options exercisable for 40,400 shares of G1’s common stock and 26,800 restricted stock units to six hired employees under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.

Atara Biotherapeutics, Inc. reported the grant of an aggregate of 31,515 restricted stock units of Atara’s common stock to four newly hired employees and stock options to purchase an aggregate of 15,227 shares of Atara’s common stock to one such newly hired employee.